Similar differences were observed with interleukin @ ( IL@ ) mRNA showing early downregulation for adalimumab responders ( week @ , -@ -LSB- @ -RSB- , P < @ ; week @ , -@ -LSB- @ -RSB- , P < @ ) compared with late downregulation for methotrexate responders ( week @ , -@ -LSB- @ -RSB- , P = @ ; week @ , -@ -LSB- @ -RSB- , P < @ ) .